Distinct genetic alterations in small cell carcinoma from different anatomic sites

Experimental Hematology and Oncology

Volumn 4, Issue 1, 2015, Pages

  Zheng, Xiaoyong ^a   Liu, Delong ^b   Fallon, John T ^a   Zhong, Minghao ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ERG;

BLADDER CARCINOMA; BLADDER SMALL CELL CARCINOMA; CANCER GROWTH; CANCER LOCALIZATION; CARCINOGENESIS; CERVICAL SMALL CELL CARCINOMA; GENE MUTATION; GENE PTEN; GENE RB1; GENE TP53; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; NONHUMAN; OVARIAN SMALL CELL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROSTATE SMALL CELL CARCINOMA; REVIEW; SMALL CELL CARCINOMA; SMALL CELL LUNG CANCER; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT CANCER; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 84977083336     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/2162-3619-4-2     Document Type: Review

References (73)

1. Mountain C: Clinical biology of small cell carcinoma: relationship to surgical therapy. Semi Oncol 1978, 5:272-9.
2. Molife L, Yan L, Vitfell-Rasmussen J, Zernhelt A, Sullivan D, Cassier P, et al.: Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 2014, 7:1. 10.1186/1756-8722-7-1.
3. Zhang J, Cao J, Li J, Zhang Y, Chen Z, Peng W, et al.: A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. J Hematol Oncol 2014, 7:22. 10.1186/1756-8722-7-22.
4. Niu F-Y, Wu Y-L: Novel agents and strategies for overcoming EGFR TKIs resistance. Experiment Hematol Oncol 2014, 3:2. 10.1186/2162-3619-3-2.
5. Wistuba II, Gazdar AF, Minna JD: Molecular genetics of small cell lung carcinoma. Semin Oncol 2001, 28:3-13. 10.1053/sonc.2001.20744.
6. Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, et al.: Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A 1990, 87:2775-9. 10.1073/pnas.87.7.2775.
7. Mori N, Yokota J, Akiyama T, Sameshima Y, Okamoto A, Mizoguchi H, et al.: Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene 1990, 5:1713-7.
8. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, et al.: PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998, 17:475-9. 10.1038/sj.onc.1201956.
9. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, et al.: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-90. 10.1038/nature08629.
10. Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT, et al.: High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol 2014, 7:47. 10.1186/s13045-014-0047-7.
11. Eble JN, Organization WH, Cancer IAR: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. WHO: IARC Press; 2004.
12. Pervez N, El-Gehani F, Joseph K, Dechaphunkul A, Kamal M, Pertschy D, et al.: Genitourinary small-cell carcinoma: a single-institution experience. Curr Oncol 2013, 20:258-64. 10.3747/co.20.1338.
13. Si Q, Dancer J, Stanton ML, Tamboli P, Ro JY, Czerniak BA, et al.: Small cell carcinoma of the kidney: a clinicopathologic study of 14 cases. Hum Pathol 2011, 42:1792-8. 10.1016/j.humpath.2011.03.005.
14. Ouzzane A, Ghoneim TP, Udo K, Verhasselt-Crinquette M, Puech P, Betrouni N, et al.: Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature. Cancer Treat Rev 2011, 37:366-72. 10.1016/j.ctrv.2010.12.005.
15. Koay EJ, Teh BS, Paulino AC, Butler EB: A surveillance, epidemiology, and end results analysis of small cell carcinoma of the bladder. Cancer 2011, 117:5325-33. 10.1002/cncr.26197.
16. Mackey JR, Au HJ, Hugh J, Venner P: Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol 1998, 159:1624-9. 10.1097/00005392-199805000-00058.
17. Bezerra SM, Lotan TL, Faraj SF, Karram S, Sharma R, Schoenberg M, et al.: GATA3 expression in small cell carcinoma of bladder and Prostate and its Potential Role in Determining Primary Tumor Origin. Hum Pathol 2014. doi: http://dx.doi.org/10.1016/j.humpath.2014.04.011
18. Jones TD, Kernek KM, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, et al.: Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol 2005, 36:718-23. 10.1016/j.humpath.2005.04.007.
19. Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, et al.: Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Modern Pathol 2000, 13:238-42. 10.1038/modpathol.3880044.
20. Ismaili N: A rare bladder cancer-small cell carcinoma: review and update. Orphanet J Rare Dis 2011, 6:75. 10.1186/1750-1172-6-75.
21. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, et al.: Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006, 30:705-12. 10.1097/00000478-200606000-00005.
22. Wang W, Epstein JI: Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008, 32:65-71. 10.1097/PAS.0b013e318058a96b.
23. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M: Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013, 12:1637-8. 10.4161/cc.24662.
24. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, et al.: Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014, 65:360-6. 10.1016/j.eururo.2013.08.052.
25. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, et al.: TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 2013, 73:7162-7. 10.1158/0008-5472.CAN-13-2498.
26. Wenk RE, Bhagavan BS, Levy R, Miller D, Weisburger W: Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 1977, 40:773-8. Publisher Full Text 10.1002/1097-0142(197708)40:2<773::AID-CNCR2820400226>3.0.CO;2-I.
27. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al.: Androgen-independent prostate cancer is a heterogeneous group of diseases lessons from a rapid autopsy program. Cancer Res 2004, 64:9209-16. 10.1158/0008-5472.CAN-04-2442.
28. Turbat-Herrera E, Herrera G, Gore I, Lott R, Grizzle W, Bonnin J: Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Archiv Pathol Lab Med 1988, 112:1100-5.
29. di Sant'Agnese PA: Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001,12(Suppl 2):S135-40. 10.1093/annonc/12.suppl_2.S135.
30. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, et al.: TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 2011, 42:11-7. 10.1016/j.humpath.2010.05.026.
31. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al.: ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011, 24:820-8. 10.1038/modpathol.2011.7.
32. Walenkamp AM, Sonke GS, Sleijfer DT: Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev 2009, 35:228-36. 10.1016/j.ctrv.2008.10.007.
33. Brennan SM, Gregory DL, Stillie A, Herschtal A, Mac Manus M, Ball DL: Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer 2010, 116:888-95. 10.1002/cncr.24858.
34. Mannion C, Park WS, Man YG, Zhuang Z, Albores-Saavedra J, Tavassoli FA: Endocrine tumors of the cervix: morphologic assessment, expression of human papillomavirus, and evaluation for loss of heterozygosity on 1p,3p, 11q, and 17p. Cancer 1998, 83:1391-400. Publisher Full Text 10.1002/(SICI)1097-0142(19981001)83:7<1391::AID-CNCR17>3.0.CO;2.
35. Hoskins P, Wong F, Swenerton K, Pike J, Manji M, McMurtrie E, et al.: Small cell carcinoma of the cervix treated with concurrent radiotherapy, cisplatin, and etoposide. Gynecol Oncol 1995, 56:218-25. 10.1006/gyno.1995.1035.
36. Carlson JW, Nucci MR, Brodsky J, Crum CP, Hirsch MS: Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis. Histopathology 2007, 51:305-12. 10.1111/j.1365-2559.2007.02790.x.
37. Atienza-Amores M, Guerini-Rocco E, Soslow RA, Park KJ, Weigelt B: Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions. Gynecol Oncol 2014,134(2):410-8. 10.1016/j.ygyno.2014.05.017.
38. Masumoto N, Fujii T, Ishikawa M, Saito M, Iwata T, Fukuchi T, et al.: P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol 2003, 34:778-83. 10.1016/S0046-8177(03)00284-3.
39. Wistuba II, Thomas B, Behrens C, Onuki N, Lindberg G, Albores-Saavedra J, et al.: Molecular abnormalities associated with endocrine tumors of the uterine cervix. Gynecol Oncol 1999, 72:3-9. 10.1006/gyno.1998.5248.
40. Ishida GM, Kato N, Hayasaka T, Saito M, Kobayashi H, Katayama Y, et al.: Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study. Int J Gynecol Pathol 2004, 23:366-72. 10.1097/01.pgp.0000139637.01977.61.
41. Clement PB: Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions. Mod Pathol 2005,18(Suppl 2):S113-29.
42. Eichhorn JH, Young RH, Scully RE: Primary ovarian small cell carcinoma of pulmonary type. A clinicopathologic, immunohistologic, and flow cytometric analysis of 11 cases. Am J Surg Pathol 1992, 16:926-38. 10.1097/00000478-199210000-00002.
43. Ikota H, Kaneko K, Takahashi S, Kawarai M, Tanaka Y, Yokoo H, et al.: Malignant transformation of ovarian mature cystic teratoma with a predominant pulmonary type small cell carcinoma component. Pathol Int 2012, 62:276-80. 10.1111/j.1440-1827.2012.02804.x.
44. Estel R, Hackethal A, Kalder M, Munstedt K: Small cell carcinoma of the ovary of the hypercalcaemic type: an analysis of clinical and prognostic aspects of a rare disease on the basis of cases published in the literature. Arch Gynecol Obstet 2011, 284:1277-82. 10.1007/s00404-011-1846-5.
45. Young RH, Oliva E, Scully RE: Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol 1994, 18:1102-16. 10.1097/00000478-199411000-00004.
46. Jelinic P, Mueller JJ, Olvera N, Dao F, Scott SN, Shah R, et al.: Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet 2014, 46:424-6. 10.1038/ng.2922.
47. Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, et al.: Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet 2014, 46:438-43. 10.1038/ng.2931.
48. Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, et al.: Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet 2014, 46:427-9. 10.1038/ng.2928.
49. Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer JG, et al.: Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 2013, 19:5351-60. 10.1158/1078-0432.CCR-13-0035.
50. Mott RT, Smoller BR, Morgan MB: Merkel cell carcinoma: a clinicopathologic study with prognostic implications. J Cutan Pathol 2004, 31:217-23. 10.1111/j.0303-6987.2004.00149.x.
51. Bobos M, Hytiroglou P, Kostopoulos I, Karkavelas G, Papadimitriou CS: Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol 2006, 28:99-104. 10.1097/01.dad.0000183701.67366.c7.
52. Feng H, Shuda M, Chang Y, Moore PS: Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008, 319:1096-100. 10.1126/science.1152586.
53. Arora R, Chang Y, Moore PS: MCV and Merkel cell carcinoma: a molecular success story. Curr Opin Virol 2012, 2:489-98. 10.1016/j.coviro.2012.05.007.
54. Arora R, Shuda M, Guastafierro A, Feng H, Toptan T, Tolstov Y, et al.: Survivin is a therapeutic target in Merkel cell carcinoma. Sci Trans Med 2012, 4:133ra156-6.
55. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A: Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011, 19:754-64. 10.1016/j.ccr.2011.04.019.
56. Park KS, Liang MC, Raiser DM, Zamponi R, Roach RR, Curtis SJ, et al.: Characterization of the cell of origin for small cell lung cancer. Cell Cycle 2011, 10:2806-15. 10.4161/cc.10.16.17012.
57. Frazier SR, Kaplan PA, Loy TS: The pathology of extrapulmonary small cell carcinoma. Semin Oncol 2007, 34:30-8. 10.1053/j.seminoncol.2006.11.017.
58. Pearse AG: The diffuse endocrine system and the implications of the APUD concept. Int Surg 1979, 64:5-7.
59. Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, et al.: Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005, 166:1533-9. 10.1016/S0002-9440(10)62369-3.
60. Ali SZ, Reuter VE, Zakowski MF: Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features. Cancer 1997, 79:356-61. Publisher Full Text 10.1002/(SICI)1097-0142(19970115)79:2<356::AID-CNCR19>3.0.CO;2.
61. Gaisa NT, Tilki D, Losen I, Dahl E, Stoehr R, Stief CG, et al.: Insights from a whole cystectomy specimen-association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ. Hum Pathol 2008, 39:1258-62. 10.1016/j.humpath.2007.12.017.
62. McCluggage WG, Kennedy K, Busam KJ: An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am J Surg Pathol 2010, 34:525-32. 10.1097/PAS.0b013e3181d1d457.
63. Rossi G, Bertolini F, Sartori G, Bigiani N, Cavazza A, Foroni M, et al.: Primary mixed adenocarcinoma and small cell carcinoma of the appendix: a clinicopathologic, immunohistochemical, and molecular study of a hitherto unreported tumor. Am J Surg Pathol 2004, 28:1233-9. 10.1097/01.pas.0000128666.89191.48.
64. Bezerra SM, Lotan TL, Faraj SF, Karram S, Sharma R, Schoenberg M, et al.: GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. Hum Pathol 2014,45(8):1682-7. 10.1016/j.humpath.2014.04.011.
65. Cecen K, Karadag MA, Demir A, Kocaaslan R: Small cell carcinoma of the prostate presenting with skin metastasis: a case report. J Med Case Rep 2014, 8:146. 10.1186/1752-1947-8-146.
66. Scott AF, Mohr DW, Ling H, Scharpf RB, Zhang P, Liptak GS: Characterization of the genomic architecture and mutational spectrum of a small cell prostate carcinoma. Genes (Basel) 2014, 5:366-84. 10.3390/genes5020366.
67. Kimura H, Uegaki M, Aoyama T, Kawai J, Hamano T, Hashimura T: Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate; a case report. Hinyokika Kiyo 2014, 60:39-43.
68. Tan H-L, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al.: Rb Loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 2013. doi:10.1158/1078-0432.CCR-13-1982
69. Burkhart DL, Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008, 8:671-82. 10.1038/nrc2399.
70. Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, Weinberg RA, et al.: Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J 1994, 13:4251-9.
71. Tan H-L, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al.: Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 2014, 20:890-903. 10.1158/1078-0432.CCR-13-1982.
72. Wang X, Jones TD, Maclennan GT, Yang XJ, Lopez-Beltran A, Eble JN, et al.: P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications. Anticancer Res 2005, 25:2001-4.
73. Salagierski M, Schalken JA: Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 2012, 187:795-801. 10.1016/j.juro.2011.10.133.